Opportunity Information: Apply for RFA AI 13 055
Apply for RFA AI 13 055
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Pilot Clinical Trials to Eliminate the Latent HIV Reservoir (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855 Allergy and Infectious Diseases Research 93.856 Microbiology and Infectious Diseases Research.
- This funding opportunity was created on Nov 25, 2013 and posted on Oct 24, 2013.
- Applicants must submit their applications by Jul 15, 2014. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $4,000,000.00 to eligible and selected applicants.
- Eligible applicants include: Small businesses For profit organizations other than small businesses Private institutions of higher education Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) County governments Special district governments Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments State governments Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Pilot Clinical Trials to Eliminate the Latent HIV Reservoir (U01) opportunity, Funding Opportunity Number RFA-AI-13-055, is a National Institutes of Health (NIH) cooperative agreement designed to support early, tightly focused clinical trials that test strategies intended to eliminate the latent HIV reservoir in adults living with HIV who are already receiving suppressive antiretroviral therapy (ART). The central scientific aim is to move beyond controlling viral replication and instead evaluate interventions that can reduce or eradicate long-lived, latently infected cells that persist despite effective ART and are widely recognized as the major barrier to a cure. Because this is a U01 cooperative agreement, applicants should expect substantial NIH program involvement during trial planning and execution, with an emphasis on coordinated milestones, close oversight, and collaborative problem-solving typical of cooperative mechanisms.
A defining feature of this FOA is that proposed pilot trials are expected to be fully integrated with laboratory-based analytical tools capable of detecting and quantifying changes in the latent reservoir. The announcement stresses measuring elimination (or meaningful reduction) of latently infected cells not only in blood, but also in tissue, reflecting the reality that HIV persistence can be compartmentalized and may not be adequately captured by peripheral blood testing alone. In practice, this means strong applications would pair clinical interventions with robust virologic and immunologic assays and include a clear plan for sampling, reservoir measurement, and interpretation of reservoir dynamics, rather than treating laboratory evaluation as an afterthought.
The opportunity falls under the NIH health research activity area and is associated with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research). The total estimated funding level listed for the FOA is $4,000,000, and the announcement explicitly indicates that there is no cost sharing or matching requirement. The FOA was posted on October 24, 2013, with an original closing date of March 7, 2014, later reflected with a current closing date of July 15, 2014, and an archive date of August 15, 2014. Even though these dates indicate the opportunity is historical/archived, the content still illustrates NIH priorities and expectations for pilot cure-oriented clinical trial design in this area.
Eligibility is broad across U.S.-based organizations and governmental entities. Eligible applicants include small businesses and other for-profit organizations, public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), and a range of government bodies such as state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities. The FOA also clarifies additional eligible applicant types, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, U.S. territories or possessions, and eligible federal agencies. Non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply, although foreign components, as defined by the NIH Grants Policy Statement, are allowed, which typically means discrete foreign collaborations can be included when well-justified and compliant with NIH policy.
Operationally, applicants are directed to the full announcement for detailed requirements and submission instructions via the NIH Grants Guide link provided (http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-055.html). For access or linking problems, the FOA provides NIH Office of Extramural Research (OER) webmaster contact information (FBOWebmaster@OD.NIH.GOV). Overall, the FOA is centered on translating cure-directed reservoir elimination concepts into carefully designed pilot clinical trials, with success dependent on rigorous integration of clinical intervention protocols and state-of-the-art reservoir measurement in both blood and tissue.
FAQs: Pilot Clinical Trials to Eliminate the Latent HIV Reservoir (U01) - RFA-AI-13-055
What is this funding opportunity?
This is the NIH Funding Opportunity Announcement (FOA) titled Pilot Clinical Trials to Eliminate the Latent HIV Reservoir (U01), Funding Opportunity Number RFA-AI-13-055. It supports early, tightly focused clinical trials that test strategies intended to eliminate (or meaningfully reduce) the latent HIV reservoir.
What type of NIH award is this?
The FOA uses a U01 cooperative agreement mechanism. A cooperative agreement means NIH program staff are expected to have substantial involvement in planning and executing the study, including coordinated milestones, close oversight, and collaborative problem-solving.
What is the central scientific goal of the FOA?
The primary aim is to move beyond simply controlling viral replication and instead evaluate interventions designed to reduce or eradicate long-lived, latently infected cells that persist despite effective antiretroviral therapy (ART). These latent reservoirs are described as a major barrier to an HIV cure.
Who is the target study population for the proposed clinical trials?
The FOA is focused on adults living with HIV who are already receiving suppressive antiretroviral therapy (ART).
What kinds of studies are expected to be proposed?
The announcement emphasizes pilot clinical trials that are early-stage and tightly focused, aimed specifically at strategies intended to eliminate or reduce the latent HIV reservoir.
How important are laboratory measurements in this FOA?
Laboratory evaluation is a defining feature. Proposed pilot trials are expected to be fully integrated with laboratory-based analytical tools capable of detecting and quantifying changes in the latent reservoir. The FOA stresses that reservoir measurement should be central to the trial design rather than treated as an add-on.
Does the FOA expect reservoir measurements only in blood?
No. The FOA specifically stresses measuring elimination (or meaningful reduction) of latently infected cells not only in blood but also in tissue, reflecting that HIV persistence can be compartmentalized and may not be adequately captured by peripheral blood testing alone.
What types of assays or tools are implied as important?
The FOA highlights the need for robust virologic and immunologic assays and a clear plan for sampling, reservoir measurement, and interpretation of reservoir dynamics. The emphasis is on analytical tools that can detect and quantify changes in the latent reservoir.
What does "cooperative agreement" mean for applicants in practice?
Applicants should expect substantial NIH program involvement during both trial planning and execution. The FOA describes this as coordinated milestones, close oversight, and collaborative problem-solving that are typical of cooperative mechanisms like the U01.
What is the estimated total funding level for this FOA?
The FOA lists a total estimated funding level of $4,000,000.
Is there a cost sharing or matching requirement?
No. The FOA explicitly indicates no cost sharing or matching requirement.
What NIH activity area does this opportunity fall under?
The FOA falls under the NIH health research activity area and is associated with CFDA numbers 93.855 (Allergy and Infectious Diseases Research) and 93.856 (Microbiology and Infectious Diseases Research).
Who is eligible to apply?
Eligibility is broad across U.S.-based organizations and governmental entities. Eligible applicants include small businesses and other for-profit organizations; public and private institutions of higher education; nonprofit organizations (including those with and without 501(c)(3) status); and multiple levels of government such as state, county, and city or township governments.
Are special district governments and independent school districts eligible?
Yes. The FOA lists special district governments and independent school districts among eligible applicant types.
Are public housing authorities eligible to apply?
Yes. The FOA includes public housing authorities/Indian housing authorities as eligible applicants.
Are minority-serving institutions included in eligibility?
Yes. The FOA explicitly lists eligibility for Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are faith-based or community-based organizations eligible?
Yes. The FOA states that faith-based or community-based organizations are eligible applicants.
Are U.S. territories or possessions eligible?
Yes. The FOA includes U.S. territories or possessions among eligible applicant types.
Are federal agencies eligible to apply?
Yes. The FOA states that eligible federal agencies may apply.
Are non-U.S. (foreign) institutions eligible to apply?
No. The FOA states that non-U.S. (foreign) institutions and non-U.S. components of U.S. organizations are not eligible to apply.
Can the project include any foreign involvement at all?
Yes, potentially. While foreign institutions cannot apply as the applicant organization, the FOA notes that foreign components, as defined by the NIH Grants Policy Statement, are allowed. This generally means discrete, well-justified foreign collaborations may be included when compliant with NIH policy.
Where can applicants find the full FOA and submission instructions?
The FOA directs applicants to the NIH Grants Guide announcement page for detailed requirements and submission instructions: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-13-055.html.
What should someone do if they have access or linking problems with the FOA webpage?
The FOA provides NIH Office of Extramural Research (OER) webmaster contact information for access/linking issues: FBOWebmaster@OD.NIH.GOV.
When was this FOA posted and what are the key dates mentioned?
The FOA was posted on October 24, 2013. It lists an original closing date of March 7, 2014, later reflected with a current closing date of July 15, 2014, and an archive date of August 15, 2014.
Is this an active funding opportunity?
The dates provided indicate the opportunity is historical/archived. Even so, the FOA content illustrates NIH priorities and expectations for pilot cure-oriented HIV reservoir elimination trial design.
What makes an application align well with the FOA’s expectations?
Based on the FOA description, strong alignment would include a carefully designed pilot clinical trial paired with rigorous virologic and immunologic assays, with a clear plan for sampling in both blood and tissue, reservoir measurement, and interpretation of reservoir dynamics, alongside readiness to work within the close-collaboration structure of a U01 cooperative agreement.
Browse more opportunities from the same category: Health
Next opportunity: FY14 Region 5 Ohio(Athens, Crawford, DelawareFranklin, Hocking, Lucas, Madison, Mahoning, Marion, Medina, Pickaway, Portage, Richland, Stark, Summit, Trumbull, Union and Wayne counties )Announcement of Anticipated Availability of Funds for Family
Previous opportunity: Administrative Supplements to NIH Awards for Validation Studies of Analytical Methods for Natural Products (Admin Supp)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA AI 13 055
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA AI 13 055) also looked into and applied for these:
| Funding Opportunity |
|---|
| FY14 Region 5 Ohio(Athens, Crawford, DelawareFranklin, Hocking, Lucas, Madison, Mahoning, Marion, Medina, Pickaway, Portage, Richland, Stark, Summit, Trumbull, Union and Wayne counties )Announcement of Anticipated Availability of Funds for Family Apply for PA FPH 14 033 Funding Number: PA FPH 14 033 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $2,924,926 |
| FY14 Region 6 Louisiana(entire state)Announcement of Anticipated Availability of Funds for Family Planning Services Grants Apply for PA FPH 14 034 Funding Number: PA FPH 14 034 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $4,745,826 |
| Reducing Loss to Follow up after Failure to Pass Newborn Hearing Screening Apply for HRSA 14 006 Funding Number: HRSA 14 006 Agency: Health Resources and Services Administration Category: Health Funding Amount: $250,000 |
| Effectiveness of Empiric Antiviral Treatment for Hospitalized Community Acquired Pneumonia during the Influenza Season Apply for RFA IP 14 001 Funding Number: RFA IP 14 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| Affordable Care Act Teaching Health Center Graduate Medical Education (THCGME) Program Apply for HRSA 14 060 Funding Number: HRSA 14 060 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Primary Care Services Resources Coordination and Development Apply for HRSA 14 001 Funding Number: HRSA 14 001 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Blood and Vascular Systems Response to Sepsis (R01) Apply for RFA HL 14 028 Funding Number: RFA HL 14 028 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| STD/HIV Disease Intervention Services Training Centers (DISTC) Apply for CDC RFA PS14 1408 Funding Number: CDC RFA PS14 1408 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| HIV Early Intervention Services (EIS Program) Existing Geographic Service Areas (EISEGA) Apply for HRSA 14 059 Funding Number: HRSA 14 059 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Replication of Key Clinical Trials Initiative (U01) Apply for PAR 13 383 Funding Number: PAR 13 383 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthening the Evidence Base and Capacity for Implementing HIV Prevention and Care and Treatment Programs in the Republic of South Africa under the United States Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH14 1403 Funding Number: CDC RFA GH14 1403 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Technical Assistance to Support AIDS Directors and HIV Prevention Program Managers in the 50 States, District of Columbia, the Commonwealth of Puerto Rico, the US Virgin Islands, and the Pacific Islands Apply for CDC RFA PS14 1405 Funding Number: CDC RFA PS14 1405 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Limited Competition Collaborative Study on the Genetics of Alcoholism (COGA) (U10) Apply for RFA AA 14 001 Funding Number: RFA AA 14 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Research Education Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, Neuroradiology and Emergency Medicine (R25) Apply for PAR 13 384 Funding Number: PAR 13 384 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| LINKAGES HIV SERVICES FOR KEY POPULATIONS Apply for SOL OAA 14 000013 Funding Number: SOL OAA 14 000013 Agency: Agency for International Development Category: Health Funding Amount: $72,000,000 |
| Systems Strengthening for Health Commodities Apply for RFA 617 14 000001 Funding Number: RFA 617 14 000001 Agency: Uganda USAID Kampala Category: Health Funding Amount: Case Dependent |
| Evaluation and Administration Coordinating Center for the Low Cost, Pragmatic, Patient Centered Randomized Controlled Intervention Trials (R01) Apply for RFA HL 14 020 Funding Number: RFA HL 14 020 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical, Epidemiologic and Ecologic Factors Impacting the Burden and Distribution of Monkeypox in Tshuapa District, Democratic Republic of the Congo Apply for RFA CK 14 002 Funding Number: RFA CK 14 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (Collaborative R01) Apply for PAR 13 391 Funding Number: PAR 13 391 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| New Computational Methods for Understanding the Functional Role of DNA Variants that are Associated with Mental Disorders (R01) Apply for PAR 13 392 Funding Number: PAR 13 392 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA AI 13 055", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.